Ascendis Pharma A/S is a biopharmaceutical company, which engages in the development of drug candidates. It specializes on its TransCon technologies to create prodrugs that provide for the ...

European equities traded in the US as American depositary receipts were trending modestly lower late Friday morning, down 0.23% to 1,399.64 on the S&P Europe Select ADR Index. Despite the decline, the ...

After turning it down a year ago, the FDA has cleared once-daily injectable Yorvipath for hypoparathyroidism from Ascendis Pharma. Yorvipath (palopegteriparatide) – previously known as TransCon ...

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Ascendis Pharma (ASND – Research Report), Tenet ...

Can BioMarin Stock Live Up to Wall Street's High Expectations? BioMarin Pharmaceutical (NASDAQ:BMRN) has been a rough investment for a long time. Over the past 10 years, shares have provided a ...

- Ascendis positioned to drive rapid revenue growth COPENHAGEN, Denmark, Jan. 12, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today provided a business and strategic roadmap update ...

Ascendis Pharma A/S (NASDAQ:ASND – Free Report) had its price objective increased by JPMorgan Chase & Co. from $165.00 to $167.00 in a report published on Wednesday morning,Benzinga reports.

stocks here >>>> Sage Therapeutics belongs to the Zacks Medical - Biomedical and Genetics industry. Another stock from the same industry, Ascendis Pharma A/S (ASND), closed the last trading ...

Stifel Nicolaus analyst Alex Thompson CFA maintained a Buy rating on Viridian Therapeutics (VRDN – Research Report) today and set a price ...

Ascendis Pharma has announced updates to its Articles of Association, detailing authorization for the issuance of warrants and share capital increases. The company’s board has the authority to ...